152 related articles for article (PubMed ID: 1909635)
1. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases.
Robins SP; Black D; Paterson CR; Reid DM; Duncan A; Seibel MJ
Eur J Clin Invest; 1991 Jun; 21(3):310-5. PubMed ID: 1909635
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.
Uebelhart D; Gineyts E; Chapuy MC; Delmas PD
Bone Miner; 1990 Jan; 8(1):87-96. PubMed ID: 2106358
[TBL] [Abstract][Full Text] [Related]
3. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
Hamdy NA; Papapoulos SE; Colwell A; Eastell R; Russell RG
Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934
[TBL] [Abstract][Full Text] [Related]
4. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.
Robins SP; Woitge H; Hesley R; Ju J; Seyedin S; Seibel MJ
J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812
[TBL] [Abstract][Full Text] [Related]
5. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
7. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine.
Hanson DA; Weis MA; Bollen AM; Maslan SL; Singer FR; Eyre DR
J Bone Miner Res; 1992 Nov; 7(11):1251-8. PubMed ID: 1466251
[TBL] [Abstract][Full Text] [Related]
8. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
9. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study.
Seibel MJ; Woitge H; Scheidt-Nave C; Leidig-Bruckner G; Duncan A; Nicol P; Ziegler R; Robins SP
J Bone Miner Res; 1994 Sep; 9(9):1433-40. PubMed ID: 7817828
[TBL] [Abstract][Full Text] [Related]
10. [Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies].
Rivero Marcotegui A; Palacios Sarrasqueta M; Grijalba Uche A; Martínez Rodríguez JL; Sorbet Zubiría MJ; García Merlo S
Rev Clin Esp; 1997 Jun; 197(6):389-92. PubMed ID: 9304127
[TBL] [Abstract][Full Text] [Related]
11. Urinary bone resorption markers in patients with metabolic bone disorders.
Ohishi T; Kushida K; Takahashi M; Kawana K; Yagi K; Kawakami K; Horiuchi K; Inoue T
Bone; 1994; 15(1):15-20. PubMed ID: 8024845
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
13. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism.
Seibel MJ; Gartenberg F; Silverberg SJ; Ratcliffe A; Robins SP; Bilezikian JP
J Clin Endocrinol Metab; 1992 Mar; 74(3):481-6. PubMed ID: 1740480
[TBL] [Abstract][Full Text] [Related]
14. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
Seibel MJ; Cosman F; Shen V; Gordon S; Dempster DW; Ratcliffe A; Lindsay R
J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
[TBL] [Abstract][Full Text] [Related]
15. Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared.
Bettica P; Moro L; Robins SP; Taylor AK; Talbot J; Singer FR; Baylink DJ
Clin Chem; 1992 Nov; 38(11):2313-8. PubMed ID: 1424129
[TBL] [Abstract][Full Text] [Related]
16. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease.
Seibel MJ; Woitge HW; Pecherstorfer M; Karmatschek M; Horn E; Ludwig H; Armbruster FP; Ziegler R
J Clin Endocrinol Metab; 1996 Sep; 81(9):3289-94. PubMed ID: 8784085
[TBL] [Abstract][Full Text] [Related]
17. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.
Paterson CR; Robins SP; Horobin JM; Preece PE; Cuschieri A
Br J Cancer; 1991 Nov; 64(5):884-6. PubMed ID: 1931610
[TBL] [Abstract][Full Text] [Related]
18. The effect of modifying dietary calcium intake pattern on the circadian rhythm of bone resorption.
Aerssens J; Declerck K; Maeyaert B; Boonen S; Dequeker J
Calcif Tissue Int; 1999 Jul; 65(1):34-40. PubMed ID: 10369731
[TBL] [Abstract][Full Text] [Related]
19. Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases.
Arbault P; Grimaux M; Pradet V; Preaudat C; Seguin P; Delmas PD
Bone; 1995 Apr; 16(4):461-7. PubMed ID: 7605707
[TBL] [Abstract][Full Text] [Related]
20. Increased urinary excretion of collagen crosslinks in girls with Ullrich-Turner syndrome.
Rauch F; Seibel M; Woitge H; Kruse K; Schönau E
Acta Paediatr; 1995 Jan; 84(1):66-9. PubMed ID: 7734903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
